2nd ALS Drug Development Summit

Kongressthemen
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/1485150-3?pid=4832

Speakers: Alain Moussy, Co-Founder and Chief Executive Officer, AB Science, and more.

https://go.evvnt.com/1485150-2?pid=4832

Frau Erin Thomas